Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

A second ascent of chemistry’s Mt. Everest

By Drug Discovery Trends Editor | December 12, 2012

In science’s equivalent of ascending Mt. Everest, researchers are reporting success in one of the most difficult challenges in synthetic chemistry—a field in which scientists reproduce natural and other substances from jars of chemicals in a lab. The feat, reported in the Journal of the American Chemical Society, involved synthesis of a rare substance with promising in vitro anti-cancer effects found naturally in tiny amounts in a Chinese medicinal herb.
   
Samuel J. Danishefsky and Feng Peng explain that maoecrystal V occurs naturally in a plant growing in China’s Yunnan province. Practitioners of Chinese traditional medicine have used the herb, called Isodon eriocalyx Hara, for hundreds of years. Scientists isolated maoecrystal V in 1994 and found that it has anti-cancer effects that warrant further examination. Large amounts would be needed to do so. However, the herb contains only small amounts of the material. In one experiment, it took more than 26 pounds of dried leaves to produce 0.00017637 oz. of maoecrystal V. In 2010, the first group of scientists succeeded in making maoecrystal V in a lab. Now, a second group has found a new route to the potential anti-cancer compound.
   
Danishefsky and Peng describe their approach as providing the basis for a synthesis that may help scientists develop a practical route to the substance for drug development and other research. It yielded a mixture of the two enantiomeric forms of maoecrystal V. They are pursuing several improvements, including a way to control the reactions to yield only a single enantiomer of the substance.

Total Synthesis of (±)-Maoecrystal V

Source: American Chemical Society


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50